-+ 0.00%
-+ 0.00%
-+ 0.00%

Medicus Pharma Secures Conditional Nasdaq Listing Compliance After Equity Financings

Benzinga·11/19/2026 12:33:06

Medicus Pharma Ltd. (NASDAQ:MDCX) on Thursday said it regained compliance with Nasdaq’s minimum shareholders’ equity requirement, securing its continued listing on The Nasdaq Capital Market.

The notice confirms that Medicus satisfies Listing Rule 5550(b)(1), which mandates at least $2.5 million in shareholders’ equity.

Medicus Pharma Equity Financings and Debt Exchange

To meet the threshold, the precision-guided biotech and life sciences company previously closed roughly $4.25 million in equity financings.

These transactions included a $3 million registered direct offering and about $1.25 million in insider-led private placements, featuring a $750,000 investment from Dr. Raza Bokhari through a controlled entity.

The company also converted $10.5 million of Streeterville Capital, LLC debt into non-convertible preferred shares.

Ongoing Nasdaq Listing Compliance Conditions

Nasdaq conditioned this compliance status on Medicus proving it still meets the minimum equity threshold in its next periodic report for the period ending December 31, 2026.

In September, Medicus Pharma announced it will concentrate all future internally sponsored clinical development for its SkinJect asset exclusively on Gorlin syndrome patients presenting with multiple basal cell carcinoma lesions, concluding further development in sporadic nodular basal cell carcinoma.

Medicus Pharma secured an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin.

MDCX Price Action: Medicus Pharma shares were up 7.19% at $1.49 during premarket trading on Thursday. The stock is trading near its 52-week low of $1.35, according to Benzinga Pro data.

Image via Shutterstock